Detection of Glucose-6-phosphate dehydrogenase (G6PD) deficiency in patients

ZP, a contract developer and manufacturer of electrochemical biosensors for point-of-care diagnostics, offers the SIA platform to efficiently guide businesses and developers from concept to product realization. This page focuses on our role in identifying Glucose-6-phosphate dehydrogenase (G6PD) deficiency.


Malaria, caused by Plasmodium species, affects millions annually. A cure requires 8-aminoquinoline therapy, targeting acute blood and dormant liver stages. Primaquine and tafenoquine, the only available hypnozoitocidal therapies, can cause acute hemolytic anemia in G6PD-deficient individuals. Clinicians are hesitant to prescribe them due to the high population prevalence of individuals with  G6PD deficiency.


The World Health Organization (WHO) recommends higher doses of transmission-blocking primaquine and tafenoquine for patients with known G6PD status, therefore highlighting the need for a G6PD point-of-care diagnostic.

Please come to ZP's next webinar to see our OEM diagnostic technology.